The first thing you learn in finance class is that the markets are efficient, meaning that asset prices fully reflect all available information.  This is a simple concept to understand, and it also helps investors read the tea leaves when it comes to the market action: stocks are discounting all available information at any time. Rallies and selloffs, while hard to predict and impossible to time, are just that — the reflections of the market’s ongoing optimism or improving outlook (which underlie the rallies) and deteriorating conditions (which drive the selloffs).  The market is also a great forward-looking mechanism. Because… Read More

The first thing you learn in finance class is that the markets are efficient, meaning that asset prices fully reflect all available information.  This is a simple concept to understand, and it also helps investors read the tea leaves when it comes to the market action: stocks are discounting all available information at any time. Rallies and selloffs, while hard to predict and impossible to time, are just that — the reflections of the market’s ongoing optimism or improving outlook (which underlie the rallies) and deteriorating conditions (which drive the selloffs).  The market is also a great forward-looking mechanism. Because it does reflect all the available information at any time, a rallying market by itself is often a bullish indicator. This is what we have today — not only a more expensive market than a few months ago, but a market that just won’t stop.  —Recommended Link— If you’re over 18 years old, you can’t be turned down for this program A simple membership form – one that takes 90 seconds or less to fill out – is all it takes to join a plan that pays out up to $12,040 a year in bonus… Read More

Much to the delight of investors, the market rallied 14% in the first three months of the year. It was the best quarterly performance for the S&P 500 since 2009. Of course, not every stock in the market has performed accordingly, but many have done well, led by the technology sector (up 20.5% in the quarter). Some investors could be reluctant to buy stocks that rallied that much, especially when the market is nearing its recent highs. And some investors might be tempted to look for a lagging stock or two in search of value — and in search of… Read More

Much to the delight of investors, the market rallied 14% in the first three months of the year. It was the best quarterly performance for the S&P 500 since 2009. Of course, not every stock in the market has performed accordingly, but many have done well, led by the technology sector (up 20.5% in the quarter). Some investors could be reluctant to buy stocks that rallied that much, especially when the market is nearing its recent highs. And some investors might be tempted to look for a lagging stock or two in search of value — and in search of a winning performance going forward. If only investing were this simple… Experienced investors know that simply buying stocks that underperform the market does not, by itself, usually result in a winning performance.  —Recommended Link— This $1,003-a-Month Income Boost Is Available to Everyone There’s a way for you to collect extra government cash. And it isn’t some “file and suspend” Social Security trick that only makes sense for a few people. This obscure opportunity allows you to collect government cash no matter how old you are or how much money you already make. Read More

For centuries, humans relied on plant-derived medicines, using — based on countless experiments and astute observation — a wide range of chemically-active elements obtained from a wide variety of plants to treat many, if not most, ailments and diseases. A more systematic study of what it is that makes certain plants medically potent had only begun in the 19th century, however, thanks to the advances in chemistry and biology. Today, the entire field of ethnopharmacology — the study of the use of plant-based or other naturally derived medicines across different cultures — has emerged. So have the related fields of… Read More

For centuries, humans relied on plant-derived medicines, using — based on countless experiments and astute observation — a wide range of chemically-active elements obtained from a wide variety of plants to treat many, if not most, ailments and diseases. A more systematic study of what it is that makes certain plants medically potent had only begun in the 19th century, however, thanks to the advances in chemistry and biology. Today, the entire field of ethnopharmacology — the study of the use of plant-based or other naturally derived medicines across different cultures — has emerged. So have the related fields of ethnomedicine, medical anthropology — not to mention food science or good old-fashioned botany — and more. The potential of plants to deliver life-changing medication has long been one of the arguments for biodiversity. It should not come as a surprise that scientists, in research labs and in the biotech industry, have also been studying cannabis with a belief that, thanks to the chemicals in the plant, it’s much more than just a popular recreational drug. One such company is a pioneer in this research and the owner of the very first prescription medication derived directly from the cannabis plant. —Recommended… Read More

I have to admit that I had not expected the tenth anniversary of this bull market to have come and gone without much fanfare. Yes, there was a celebration — after all, the 10-year bull market is the longest since World War II, and the S&P 500 is up more than 300% — but it wasn’t as omnipresent as I had anticipated.  Instead, investors have been reveling in another, albeit related milestone — the market recovery from the fourth-quarter 2018 selloff in the strongest three-month performance since the third quarter of 2009.  This strength has helped the market to recover… Read More

I have to admit that I had not expected the tenth anniversary of this bull market to have come and gone without much fanfare. Yes, there was a celebration — after all, the 10-year bull market is the longest since World War II, and the S&P 500 is up more than 300% — but it wasn’t as omnipresent as I had anticipated.  Instead, investors have been reveling in another, albeit related milestone — the market recovery from the fourth-quarter 2018 selloff in the strongest three-month performance since the third quarter of 2009.  This strength has helped the market to recover much of the fourth-quarter losses and, as a result, post strong positive year-over-year returns.  One-Year Sector Performance (As of March 31) Source: S&P Global Market Intelligence Nearly every corner of the market has turned a strong performance over the past year. The market, as represented by the S&P 500, is up 7.3% year-over-year — helped, without a doubt, by the first-quarter rally. But even as every single market sector turned out a positive performance in the first quarter of 2019, some — such as energy, materials and financials — are still down compared with a year ago.  Let’s… Read More

In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma space.  In order to help make up for the revenue that will be lost from expiring patents on blockbuster drugs, big pharma, flush with cash, typically goes out and buys a new revenue stream — in the form of companies that have a proven or promising drug in the pipeline. After all, it can be cheaper and more efficient for big pharma to buy a new drug than to develop one in-house. We live this notion… Read More

In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma space.  In order to help make up for the revenue that will be lost from expiring patents on blockbuster drugs, big pharma, flush with cash, typically goes out and buys a new revenue stream — in the form of companies that have a proven or promising drug in the pipeline. After all, it can be cheaper and more efficient for big pharma to buy a new drug than to develop one in-house. We live this notion every day, both as investors, observing and often benefitting from M&A in the industry, and as consumers, feeling squeezed by the rising costs of many important medications — a process that, in part, stems from the reduced competition (which is also a consequence of a more intense M&A). #-ad_banner-#But the trend is clear, as is the need and the drive of the larger companies to buy their smaller counterparts. It’s the safer route in an environment where new drugs take a long, costly and risky road from an idea to the market. Of course, it’s not only the revenue stream… Read More

What’s better than a game-changer that capitalizes on a growth opportunity?  Answer: a game-changer that capitalizes on more than one growth opportunity. This is how Advanced Micro Devices (Nasdaq: AMD) looks like these days. The company has built a sustainable business… a business that doesn’t just depend on strong demand from one particular sector or industry — but rather is set to grow and conquer new markets. In many ways, the chipmaker just might be the perfect game-changer. It’s no wonder then, that we own it in the portfolio of my premium newsletter, Game-Changing Stocks. In fact, we’re up more… Read More

What’s better than a game-changer that capitalizes on a growth opportunity?  Answer: a game-changer that capitalizes on more than one growth opportunity. This is how Advanced Micro Devices (Nasdaq: AMD) looks like these days. The company has built a sustainable business… a business that doesn’t just depend on strong demand from one particular sector or industry — but rather is set to grow and conquer new markets. In many ways, the chipmaker just might be the perfect game-changer. It’s no wonder then, that we own it in the portfolio of my premium newsletter, Game-Changing Stocks. In fact, we’re up more than 92% on the stock in just under 18 months. Today, I want to walk you through some of the moves AMD has made recently that illustrate this point — and why it’s still a good option for investors today. —Recommended Link— This changed EVERYTHING we thought we knew about investing… It took months to put together. but our industry expert just revealed a revolutionary (and surprisingly legal) stock market “hack” that has already brought in $2,434 in just 16 days. This simple hack could be the key to unlocking the full potential of your portfolio (while reducing your… Read More

There’s always a fascination with low-priced small-cap stocks. Maybe it’s the “venture capital-like” approach that it brings, or maybe it’s the dream of getting in on the ground floor of the next Facebook (Nasdaq: FB) or Amazon (Nasdaq: AMZN). Whatever the case might be, there’s no denying that small-cap stocks can provide investors with astronomical returns. You’re more likely to see a small-cap stock with strong growth prospects return triple digits in a year than you are a blue-chip stock. —Recommended Link— Wall Street won’t tell you about this… but we just uncovered a bombshell… From custom coded cures… Read More

There’s always a fascination with low-priced small-cap stocks. Maybe it’s the “venture capital-like” approach that it brings, or maybe it’s the dream of getting in on the ground floor of the next Facebook (Nasdaq: FB) or Amazon (Nasdaq: AMZN). Whatever the case might be, there’s no denying that small-cap stocks can provide investors with astronomical returns. You’re more likely to see a small-cap stock with strong growth prospects return triple digits in a year than you are a blue-chip stock. —Recommended Link— Wall Street won’t tell you about this… but we just uncovered a bombshell… From custom coded cures to blood cell-sized “nanobots” one company is paving the way towards ending disease as we know it… We’ve got the company and the ticker that could make you millions. ​Click here for the full details. That’s why I decided it would be fun to fire up my Maximum Profit system and scan the market for small-cap stocks (market cap under $2 billion) with share prices under $10. I also wanted to make sure we weren’t getting thinly-traded stocks, or those with low volume, so I made sure that at least 75,000 shares change hands on average daily. Using a… Read More

Where do you go to find the very best growth stories?  Clearly, some of the best innovators come from the tech and the health-care industries. And so, almost by default, most of my Fast-Track Millionaire portfolio stocks belong to those two major growth sectors.  But what about the rest of the economy? Does it not generate any innovation or significant profit opportunities?  Of course, it does. And that’s what today’s piece is all about… —Recommended Link— This “Guaranteed Income Strategy” Is Batting .905 Since 2013, one income investment has been knocking it out of the park. In… Read More

Where do you go to find the very best growth stories?  Clearly, some of the best innovators come from the tech and the health-care industries. And so, almost by default, most of my Fast-Track Millionaire portfolio stocks belong to those two major growth sectors.  But what about the rest of the economy? Does it not generate any innovation or significant profit opportunities?  Of course, it does. And that’s what today’s piece is all about… —Recommended Link— This “Guaranteed Income Strategy” Is Batting .905 Since 2013, one income investment has been knocking it out of the park. In fact, the “Guaranteed Income Strategy” has banked 191 winners out of 211 trades — generating a $140,490 windfall. If collecting instant cash and winning 90.5% of the time sounds good to you, then grab the details on how you can pocket your first instant cash this Wednesday. To illustrate my point, look no further than a company like Tesla (Nasdaq: TSLA). Believe it or not, Tesla is an industrial company by any official classification. And regardless what you may think of the recent, well-publicized missteps of CEO Elon Musk, is indeed an innovator. And what’s more,… Read More

You know you’ve stumbled across something good when other financial publishing outlets begin using it.  It is a bit of a catch-22, however, because on the one hand it’s an idea that we here at StreetAuthority developed and made popular, but don’t get credit for… On the other hand, imitation is the sincerest form of flattery. To be sure, it’s not as if we developed an iPhone model that every other competitor began mimicking, or some other ground-breaking technology. We simply came up with giving a sound, time-tested way of investing, a couple of catchy phrases. They aren’t proprietary, trademarked… Read More

You know you’ve stumbled across something good when other financial publishing outlets begin using it.  It is a bit of a catch-22, however, because on the one hand it’s an idea that we here at StreetAuthority developed and made popular, but don’t get credit for… On the other hand, imitation is the sincerest form of flattery. To be sure, it’s not as if we developed an iPhone model that every other competitor began mimicking, or some other ground-breaking technology. We simply came up with giving a sound, time-tested way of investing, a couple of catchy phrases. They aren’t proprietary, trademarked or patented. Nor should they be. But now, whenever I come across them on the Web, I simply smile and know that the history behind these popular headlines and marketing commentary all started here. You see, we’ve published thousands of in-depth research reports. Everything from high-dividend payers, game-changing innovations, top tech stocks, best plays in emerging markets — you name it, we’ve told you how to profit from it. But there are two pieces of research that have spread like wildfire since we first began publishing them over a decade ago. In fact, I hardly even mention or use the… Read More

Once again, an old-school company fails to keep up. Or just fails. General Electric (NYSE: GE), which just a month or so ago seemed to be out of the woods after two years of declining earnings and dividend cuts, just warned investors of another year of lower profits and forecasted that its industrial operations — formerly its bread and butter — could be up to $2 billion cash-flow negative this year. Just a month ago, the market was cheering GE’s decision to sell one of its important assets, the company’s biopharma unit, to Danaher (NYSE: DHR) for $21.4 billion. The… Read More

Once again, an old-school company fails to keep up. Or just fails. General Electric (NYSE: GE), which just a month or so ago seemed to be out of the woods after two years of declining earnings and dividend cuts, just warned investors of another year of lower profits and forecasted that its industrial operations — formerly its bread and butter — could be up to $2 billion cash-flow negative this year. Just a month ago, the market was cheering GE’s decision to sell one of its important assets, the company’s biopharma unit, to Danaher (NYSE: DHR) for $21.4 billion. The deal is expected to close in the fourth quarter. But the proceeds won’t be reinvested in the business. Rather, the proceeds will be used to reduce GE’s enormous debt. At year-end, GE had $108 billion in debt (almost as much as it had taken in revenue during the entire year, which was $121.6 billion). ​ The decision to reduce debt is the right one. The size of a company’s debt matters, especially when business suddenly slows. Too much debt can often lead to bankruptcy — even in a strong economy like ours today, let alone in leaner times. But when… Read More